TY - JOUR
T1 - Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma
AU - Whitlock, Richard S.
AU - Loo, Caitlyn
AU - Patel, Kalyani
AU - Bista, Ranjan
AU - Goss, John A.
AU - Heczey, Andras
AU - Khan, Osman
AU - Lopez-Terrada, Dolores
AU - Masand, Prakash
AU - Nguyen, Haithuy
AU - Mahvash, Armeen
AU - Vasudevan, Sanjeev A.
AU - Kukreja, Kamlesh
N1 - Publisher Copyright:
© 2021 Lippincott Williams and Wilkins. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Background: Children with unresectable hepatocellular carcinoma (HCC) have a poor prognosis and limited treatment options. Transarterial radioembolization (TARE) using Yttrium-90 (Y90) has emerged as a potential bridge therapy to hepatic resection or transplantation for HCC with very limited studies in children. Observations: Here we present the clinical course of 2 children successfully treated with TARE Y90 for initially unresectable fibrolamellar HCC (FL-HCC) and bridged to partial hemihepatectomy with >1-year overall survival post-TARE. Conclusion: Although there have been prior published reports of pediatric patients with HCC being treated with TARE Y90 and some being able to undergo subsequent orthotopic liver transplantation, this is the first report of pediatric HCC patients treated with TARE Y90 as a bridge to nontransplant resections and going on to have >1-year overall survival.
AB - Background: Children with unresectable hepatocellular carcinoma (HCC) have a poor prognosis and limited treatment options. Transarterial radioembolization (TARE) using Yttrium-90 (Y90) has emerged as a potential bridge therapy to hepatic resection or transplantation for HCC with very limited studies in children. Observations: Here we present the clinical course of 2 children successfully treated with TARE Y90 for initially unresectable fibrolamellar HCC (FL-HCC) and bridged to partial hemihepatectomy with >1-year overall survival post-TARE. Conclusion: Although there have been prior published reports of pediatric patients with HCC being treated with TARE Y90 and some being able to undergo subsequent orthotopic liver transplantation, this is the first report of pediatric HCC patients treated with TARE Y90 as a bridge to nontransplant resections and going on to have >1-year overall survival.
UR - http://www.scopus.com/inward/record.url?scp=85118498385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85118498385&partnerID=8YFLogxK
U2 - 10.1097/MPH.0000000000002089
DO - 10.1097/MPH.0000000000002089
M3 - Article
C2 - 33769387
AN - SCOPUS:85118498385
SN - 1077-4114
VL - 43
SP - E1181-E1185
JO - Journal of Pediatric Hematology/Oncology
JF - Journal of Pediatric Hematology/Oncology
IS - 8
ER -